Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

SUMMARY Objective: The FACT study (Fosamax Actonel Comparison Trial) was a 1-year head-to-head trial comparing the efficacy and tolerability of once weekly (OW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis. The present analysis was performed to determin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current medical research and opinion 2004-12, Vol.20 (12), p.2031-2041
Hauptverfasser:	Sebba, Anthony I., Bonnick, Sydney Lou, Kagan, Risa, Thompson, Desmond E., Skalky, Carol S., Chen, Erluo, Papp, Anne E. de
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Alendronate Biochemical markers of bone turnover Bone Density Bone mineral density Bone Resorption Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - adverse effects Calcium Channel Blockers - therapeutic use Double-Blind Method Drug Administration Schedule Etidronic Acid - administration & dosage Etidronic Acid - adverse effects Etidronic Acid - analogs & derivatives Etidronic Acid - therapeutic use Female Gastrointestinal tolerability Humans Osteoporosis - drug therapy Postmenopause Risedronate Risedronic Acid Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!